Vascular Biogenics Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VBLT Nasdaq 8731 https://www.vblrx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vascular Biogenics Ltd

VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update - May 15th, 2023 8:01 pm
Vascular Biogenics Full Year 2022 Earnings: US$0.42 loss per share (vs US$0.45 loss in FY 2021) - Mar 17th, 2023 10:37 am
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update - Mar 14th, 2023 12:00 pm
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash - Mar 9th, 2023 1:00 pm
VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement - Feb 23rd, 2023 12:00 pm
VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash - Feb 16th, 2023 1:00 pm
13 Best Biotech Penny Stocks To Buy Now - Nov 29th, 2022 10:43 pm
Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates - Nov 15th, 2022 12:55 am
VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 14th, 2022 9:05 pm
OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates - Nov 10th, 2022 10:35 pm
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07 - Sep 2nd, 2022 4:36 pm
Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose - Sep 2nd, 2022 4:29 pm
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - Sep 1st, 2022 8:30 pm
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product - Sep 1st, 2022 4:45 pm
Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates - Aug 15th, 2022 9:35 pm
VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options - Aug 15th, 2022 8:05 pm
Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for - Aug 8th, 2022 2:00 pm
VBL Therapeutics Announces Workforce Reduction - Aug 2nd, 2022 12:00 pm
Vascular Biogenics (VBLT) Down, Ovarian Cancer Study Fails - Jul 21st, 2022 3:49 pm
Read Why VBL Therapeutics Shares Are Falling To a 52-Week Low - Jul 20th, 2022 11:35 am